Beta-Amyloid (1-42), Human

Beta-Amyloid (1-42) is a key molecule in Alzheimer's disease (AD) research, known for its high aggregation propensity and neurotoxicity. It plays a critical role in synaptic dysfunction, neuroinflammation, and oxidative stress, making it a central target for understanding AD pathogenesis. As a biomarker, reduced Aβ(1-42) levels and Aβ(1-42)/Aβ(1-40) ratios in cerebrospinal fluid are vital for diagnosis. It is also widely used in neurotoxicity models for drug screening and mechanistic studies. Therapeutic efforts focus on monoclonal antibodies (e.g., Aducanumab), aggregation inhibitors, and enhanced clearance strategies.

Specifications

References:

1. He, W., Barlogie, B., & Epstein, J. (2004). Amyloid beta protein (1-42) induces neuronal death through the p75 neurotrophin receptor. The Journal of Neuroscience, 24(33), 9016–9021.

2. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., ... Selkoe, D. J. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine, 14(8), 837–842.

3. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., ... Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537(7618), 50–56.

4. Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology, 64(3), 343–349.

5. Luo, Q., Lin, Y., & Zhang, Z. (2020). Self-assembled peptide nanomaterials for targeted delivery of amyloid beta inhibitors. Chemical Society Reviews, 49(17), 5619–5637.

Hot Tags: Beta-Amyloid (1-42), Human, peptides for cancer research, peptides for diagnostic assays, peptides ordering, Cyclo RGDfV , Cyclo RGDyK Mal , peptides for infectious disease research